Primary tabs
The list of publications is indicative and may not include all publications.
Hydrochlorothiazide vs. chlorthalidone as the optimal diuretic for the management of hypertension..
Curr Pharm Des. 19(21), 3766-72.
(2013).
The clinical significance and primary determinants of hirsutism in patients with polycystic ovary syndrome..
Eur J Endocrinol. 168(6), 871-7.
(2013).
Lifestyle intervention and anti-obesity therapies in the polycystic ovary syndrome: impact on metabolism and fertility..
Endocrine. 44(3), 583-90.
(2013).
The increase in thyroid cancer incidence is not only due to papillary microcarcinomas: a 40-year study in 1 778 patients..
Exp Clin Endocrinol Diabetes. 121(7), 397-401.
(2013).
Age- and body mass index-related differences in the prevalence of metabolic syndrome in women with polycystic ovary syndrome..
Gynecol Endocrinol. 29(10), 926-30.
(2013).
Plasma von Willebrand factor antigen levels are elevated in the classic phenotypes of polycystic ovary syndrome..
Hormones (Athens). 11(1), 77-85.
(2012).
Cardiοvascular diseases in pregnancy..
Am J Cardiovasc Dis. 2(2), 96-101.
(2012).
Weight loss significantly reduces serum lipocalin-2 levels in overweight and obese women with polycystic ovary syndrome..
Gynecol Endocrinol. 28(1), 20-4.
(2012).
Plasma plasminogen activator inhibitor-1 levels in the different phenotypes of the polycystic ovary syndrome..
Endocr J. 59(1), 21-9.
(2012).
Lipid lowering agents and the endothelium: an update after 4 years..
Curr Vasc Pharmacol. 10(1), 33-41.
(2012).
Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study..
Hum Reprod. 27(2), 541-9.
(2012).
Non-alcoholic fatty liver disease in type 2 diabetes: pathogenesis and treatment options..
Curr Vasc Pharmacol. 10(2), 162-72.
(2012).
Residual cardiac risk reduction beyond lipid lowering..
Hellenic J Cardiol. 52(3), 197-203.
(2011).
Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment..
Open Cardiovasc Med J. 5, 24-34.
(2011).
Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases..
Open Cardiovasc Med J. 5, 85-9.
(2011).
Atherosclerotic renal artery stenosis: an update on diagnosis and management..
Curr Vasc Pharmacol. 9(4), 465-70.
(2011).
Preventing Cardio-renal Syndrome Rather than Treating It: Could Statins Play A Role?.
Open Cardiovasc Med J. 5, 226-30.
(2011).
Effect of a plant stanol ester-containing spread, placebo spread, or Mediterranean diet on estimated cardiovascular risk and lipid, inflammatory and haemostatic factors..
Nutr Metab Cardiovasc Dis. 21(3), 213-21.
(2011).
The effect of weight loss and treatment with metformin on serum vaspin levels in women with polycystic ovary syndrome..
Endocr J. 58(4), 237-46.
(2011).
Pages
- « πρώτη
- ‹ προηγούμενη
- …
- 3
- 4
- 5
- 6
- 7
- …
- επόμενη ›
- τελευταία »